collection
MENU ▼
Read by QxMD icon Read
search

Osteoporosis

shared collection
89 papers 0 to 25 followers
https://www.readbyqxmd.com/read/28432596/exploiting-the-wnt-signaling-pathway-for-clinical-purposes
#1
REVIEW
Mark L Johnson, Robert R Recker
PURPOSE OF REVIEW: The goal of this paper is to evaluate critically the literature published over the past 3 years regarding the Wnt signaling pathway. The Wnt pathway was found to be involved in bone biology in 2001-2002 with the discovery of a (G171V) mutation in the lipoprotein receptor-related protein 5 (LRP5) that resulted in high bone mass and another mutation that completely inactivated Lrp5 function and resulted in osteoporosis pseudoglioma syndrome (OPPG). The molecular biology has been complex, and very interesting...
April 21, 2017: Current Osteoporosis Reports
https://www.readbyqxmd.com/read/28379394/serum-25-hydroxyvitamin-d-insufficiency-in-search-of-a-bone-disease
#2
Sonali Shah, Cherie Chiang, Ken Sikaris, Zhong Lu, Minh Bui, Roger Zebaze, Ego Seeman
Introduction: Vitamin D 'insufficiency' and 'deficiency' are defined as a serum 25-hydroxyvitamin D (25(OH)D) below 75 and 30 nmol/L respectively. We aimed to determine whether these values signal hypocalcaemia and hypophosphatemia, secondary hyperparathyroidism, high bone remodeling, low areal bone mineral density (aBMD), microstructural deterioration, or reduced matric mineralization density (MMD), and so suggest whether bone fragility is present. Method: Concentrations of 25(OH)D, calcium, phosphate, creatinine and parathyroid hormone (PTH) were measured in 11,855 subjects...
March 30, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28416991/can-denosumab-be-a-substitute-competitor-or-complement-to-bisphosphonates
#3
REVIEW
Su Young Kim, Hwoe Gyeong Ok, Christof Birkenmaier, Kyung Hoon Kim
Osteoblasts, originating from mesenchymal cells, make the receptor activator of the nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in order to control differentiation of activated osteoclasts, originating from hematopoietic stem cells. When the RANKL binds to the RANK of the pre-osteoclasts or mature osteoclasts, bone resorption increases. On the contrary, when OPG binds to the RANK, bone resorption decreases. Denosumab (AMG 162), like OPG (a decoy receptor), binds to the RANKL, and reduces binding between the RANK and the RANKL resulting in inhibition of osteoclastogenesis and reduction of bone resorption...
April 2017: Korean Journal of Pain
https://www.readbyqxmd.com/read/28359721/western-osteoporosis-alliance-clinical-practice-series-evaluating-the-balance-of-benefits-and-risks-of-long-term-osteoporosis-therapies
#4
REVIEW
D A Hanley, M R McClung, K S Davison, L Dian, S T Harris, P D Miller, E M Lewiecki, D L Kendler
Osteoporosis is a chronic disease that requires life-long strategies to reduce fracture risk. Few trials have investigated the balance of benefits and risk with long-term use of osteoporosis therapies and fewer still have investigated the consequences of treatment discontinuation. The best available evidence suggests that up to 10 years of treatment with an oral bisphosphonate maintains the degree of fracture risk reduction observed in the three-year registration trials. With denosumab, 10 years of therapy appears to provide fracture risk reduction similar to or better than that observed in the three-year registration trial...
March 27, 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/28283938/seasonal-variation-in-internet-searches-for-vitamin-d
#5
Rebecca J Moon, Elizabeth M Curtis, Justin H Davies, Cyrus Cooper, Nicholas C Harvey
Internet search rates for "vitamin D" were explored using Google Trends. Search rates increased from 2004 until 2010 and thereafter displayed a seasonal pattern peaking in late winter. This knowledge could help guide the timing of public health interventions aimed at managing vitamin D deficiency. PURPOSE: The Internet is an important source of health information. Analysis of Internet search activity rates can provide information on disease epidemiology, health related behaviors and public interest...
December 2017: Archives of Osteoporosis
https://www.readbyqxmd.com/read/28283537/increased-osteoclastogenesis-in-patients-with-vertebral-fractures-following-discontinuation-of-denosumab-treatment
#6
Athanasios D Anastasilakis, Maria P Yavropoulou, Polyzois Makras, Grigorios T Sakellariou, Fotini Papadopoulou, Spyridon Gerou, Socrates E Papapoulos
OBJECTIVE: To test the hypothesis that rebound of bone remodeling is responsible for clinical vertebral fractures reported in a few patients with osteoporosis after cessation of denosumab treatment. DESIGN: In this case-control study we compared clinical and biochemical characteristics of postmenopausal women with clinical vertebral fractures 8-16 months after the last injection of denosumab (Dmab/Fx+, n = 5) with those of treatment-naïve women with such fractures (Fx+, n = 5)...
June 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/28240371/clinical-features-of-24-patients-with-rebound-associated-vertebral-fractures-following-denosumab-discontinuation-systematic-review-and-additional-cases
#7
Athanasios D Anastasilakis, Stergios A Polyzos, Polyzois Makras, Berengere Aubry-Rozier, Stella Kaouri, Olivier Lamy
We aimed to study the clinical and imaging characteristics of patients sustaining vertebral fractures after denosumab discontinuation. For this purpose we conducted a computerized advanced literature search which identified 13 published cases and we additionally included another eleven new cases from our centers. Twenty-four postmenopausal women with vertebral fracture(s) following denosumab discontinuation, experiencing 112 fractures in total, were analyzed. The mean number of fractures per patient was 4.7...
February 27, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/28193701/osteoblastic-lrp4-promotes-osteoclastogenesis-by-regulating-atp-release-and-adenosine-a2ar-signaling
#8
Lei Xiong, Ji-Ung Jung, Hao-Han Guo, Jin-Xiu Pan, Xiang-Dong Sun, Lin Mei, Wen-Cheng Xiong
Bone homeostasis depends on the functional balance of osteoblasts (OBs) and osteoclasts (OCs). Lrp4 is a transmembrane protein that is mutated in patients with high bone mass. Loss of Lrp4 in OB-lineage cells increases bone mass by elevating bone formation by OBs and reducing bone resorption by OCs. However, it is unclear how Lrp4 deficiency in OBs impairs osteoclastogenesis. Here, we provide evidence that loss of Lrp4 in the OB lineage stabilizes the prorenin receptor (PRR) and increases PRR/V-ATPase-driven ATP release, thereby enhancing the production of the ATP derivative adenosine...
March 6, 2017: Journal of Cell Biology
https://www.readbyqxmd.com/read/28144701/observations-following-discontinuation-of-long-term-denosumab-therapy
#9
M R McClung, R B Wagman, P D Miller, A Wang, E M Lewiecki
Stopping denosumab after 8 years of continued treatment was associated with bone loss during a 1-year observation study in patients who were not prescribed osteoporosis treatment. Bone loss was attenuated in patients who began another osteoporosis therapy. Treatment to prevent bone loss upon stopping denosumab should be considered. INTRODUCTION: This study aimed to understand osteoporosis management strategies during a 1-year observational follow-up after up to 8 years of denosumab treatment in a phase 2 study...
May 2017: Osteoporosis International
https://www.readbyqxmd.com/read/26348019/mutations-in-known-monogenic-high-bone-mass-loci-only-explain-a-small-proportion-of-high-bone-mass-cases
#10
Celia L Gregson, Lawrie Wheeler, Sarah A Hardcastle, Louise H Appleton, Kathryn A Addison, Marieke Brugmans, Graeme R Clark, Kate A Ward, Margaret Paggiosi, Mike Stone, Joegi Thomas, Rohan Agarwal, Kenneth E S Poole, Eugene McCloskey, William D Fraser, Eleanor Williams, Alex N Bullock, George Davey Smith, Matthew A Brown, Jon H Tobias, Emma L Duncan
High bone mass (HBM) can be an incidental clinical finding; however, monogenic HBM disorders (eg, LRP5 or SOST mutations) are rare. We aimed to determine to what extent HBM is explained by mutations in known HBM genes. A total of 258 unrelated HBM cases were identified from a review of 335,115 DXA scans from 13 UK centers. Cases were assessed clinically and underwent sequencing of known anabolic HBM loci: LRP5 (exons 2, 3, 4), LRP4 (exons 25, 26), SOST (exons 1, 2, and the van Buchem's disease [VBD] 52-kb intronic deletion 3')...
March 2016: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/27742500/sclerostin-deficiency-in-humans
#11
Antoon H van Lierop, Natasha M Appelman-Dijkstra, Socrates E Papapoulos
Sclerosteosis and van Buchem disease are two rare bone sclerosing dysplasias caused by genetic defects in the synthesis of sclerostin. In this article we review the demographic, clinical, biochemical, radiological, and histological characteristics of patients with sclerosteosis and van Buchem disease that led to a better understanding of the role of sclerostin in bone metabolism in humans and we discuss the relevance of these findings for the development of new therapeutics for the treatment of patients with osteoporosis...
March 2017: Bone
https://www.readbyqxmd.com/read/28079119/interleukin-32-gamma-stimulates-bone-formation-by-increasing-mir-29a-in-osteoblastic-cells-and-prevents-the-development-of-osteoporosis
#12
Eun-Jin Lee, Sang-Min Kim, Bongkun Choi, Eun-Young Kim, Yeon-Ho Chung, Eun-Ju Lee, Bin Yoo, Chang-Keun Lee, Seokchan Hong, Beom-Jun Kim, Jung-Min Koh, Soo-Hyun Kim, Yong-Gil Kim, Eun-Ju Chang
Interleukin-32 gamma (IL-32γ) is a recently discovered cytokine that is elevated in inflamed tissues and contributes to pathogenic features of bone in human inflammatory rheumatic diseases. Nevertheless, the role of IL-32γ and its direct involvement in bone metabolism is unclear. We investigated the molecular mechanism of IL-32γ in bone remodeling and the hypothetical correlation between IL-32γ and disease activity in osteoporosis patients. Transgenic (TG) mice overexpressing human IL-32γ showed reduced bone loss with advancing age, increased bone formation, and high osteogenic capacity of osteoblast compared to wild-type (WT) mice through the upregulation of miR-29a, which caused a reduction of Dickkopf-1 (DKK1) expression...
January 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/23074140/van-buchem-disease-clinical-biochemical-and-densitometric-features-of-patients-and-disease-carriers
#13
Antoon H van Lierop, Neveen A T Hamdy, Martje E van Egmond, Egbert Bakker, Freek G Dikkers, Socrates E Papapoulos
Van Buchem disease (VBD) is a rare bone sclerosing dysplasia caused by the lack of a regulatory element of the SOST gene, which encodes for sclerostin, an osteocyte-derived negative regulator of bone formation. We studied the demographic, clinical, biochemical, and densitometric features of 15 patients with VBD (12 adults and 3 children) and 28 related carriers of the gene mutation. The most common clinical findings in patients were facial palsy (100%) and various degrees of hearing impairment (93%); raised intracranial pressure had been documented in 20%...
April 2013: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/27980413/high-bone-turnover-elevates-the-risk-of-denosumab-induced-hypocalcemia-in-women-with-postmenopausal-osteoporosis
#14
Koji Ishikawa, Takashi Nagai, Keizo Sakamoto, Kenji Ohara, Takeshi Eguro, Hiroshi Ito, Yoichi Toyoshima, Akatsuki Kokaze, Tomoaki Toyone, Katsunori Inagaki
Hypocalcemia is the most common major adverse event in patients with osteoporosis receiving the bone resorption inhibitor denosumab; however, limited information is available regarding risk factors of hypocalcemia. Therefore, this study aimed to identify the risk factors of hypocalcemia induced by denosumab treatment for osteoporosis. We retrospectively reviewed the records of patients who had received initial denosumab supplemented with activated vitamin D for osteoporosis. Serum levels of the following bone turnover markers (BTMs) were measured at baseline: bone-specific alkaline phosphatase (BAP), total N-terminal propeptide of type 1 procollagen (P1NP), tartrate-resistant acid phosphatase 5b (TRACP-5b), and urinary cross-linked N-telopeptide of type 1 collagen (NTX)...
2016: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/27888287/wnt-signaling-and-cellular-metabolism-in-osteoblasts
#15
REVIEW
Courtney M Karner, Fanxin Long
The adult human skeleton is a multifunctional organ undergoing continuous remodeling. Homeostasis of bone mass in a healthy adult requires an exquisite balance between bone resorption by osteoclasts and bone formation by osteoblasts; disturbance of such balance is the root cause for various bone disorders including osteoporosis. To develop effective and safe therapeutics to modulate bone formation, it is essential to elucidate the molecular mechanisms governing osteoblast differentiation and activity. Due to their specialized function in collagen synthesis and secretion, osteoblasts are expected to consume large amounts of nutrients...
May 2017: Cellular and Molecular Life Sciences: CMLS
https://www.readbyqxmd.com/read/27742498/role-and-mechanism-of-action-of-sclerostin-in-bone
#16
Jesus Delgado-Calle, Amy Y Sato, Teresita Bellido
After discovering that lack of Sost/sclerostin expression is the cause of the high bone mass human syndromes Van Buchem disease and sclerosteosis, extensive animal experimentation and clinical studies demonstrated that sclerostin plays a critical role in bone homeostasis and that its deficiency or pharmacological neutralization increases bone formation. Dysregulation of sclerostin expression also underlies the pathophysiology of skeletal disorders characterized by loss of bone mass, as well as the damaging effects of some cancers in bone...
March 2017: Bone
https://www.readbyqxmd.com/read/27811938/bone-romosozumab-getting-there-but-not-quite-yet
#17
Socrates E Papapoulos
No abstract text is available yet for this article.
December 2016: Nature Reviews. Endocrinology
https://www.readbyqxmd.com/read/27746742/molecular-mechanisms-of-obesity-induced-osteoporosis-and-muscle-atrophy
#18
Bipradas Roy, Mary E Curtis, Letimicia S Fears, Samuel N Nahashon, Hugh M Fentress
Obesity and osteoporosis are two alarming health disorders prominent among middle and old age populations, and the numbers of those affected by these two disorders are increasing. It is estimated that more than 600 million adults are obese and over 200 million people have osteoporosis worldwide. Interestingly, both of these abnormalities share some common features including a genetic predisposition, and a common origin: bone marrow mesenchymal stromal cells. Obesity is characterized by the expression of leptin, adiponectin, interleukin 6 (IL-6), interleukin 10 (IL-10), monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-α), macrophage colony stimulating factor (M-CSF), growth hormone (GH), parathyroid hormone (PTH), angiotensin II (Ang II), 5-hydroxy-tryptamine (5-HT), Advance glycation end products (AGE), and myostatin, which exert their effects by modulating the signaling pathways within bone and muscle...
2016: Frontiers in Physiology
https://www.readbyqxmd.com/read/27776363/calcium-intake-and-cardiovascular-disease-risk-an-updated-systematic-review-and-meta-analysis
#19
REVIEW
Mei Chung, Alice M Tang, Zhuxuan Fu, Ding Ding Wang, Sydne Jennifer Newberry
Background: Conflicting evidence exists regarding potential cardiovascular risks associated with high levels of calcium intake. Purpose: To update and reanalyze 2 systematic reviews to examine the effects of calcium intake on cardiovascular disease (CVD) among generally healthy adults. Data Sources: MEDLINE; Cochrane Central Register of Controlled Trials; Scopus, including EMBASE; and previous evidence reports from English-language publications from 1966 to July 2016...
December 20, 2016: Annals of Internal Medicine
https://www.readbyqxmd.com/read/27781192/staged-correction-of-severe-thoracic-kyphosis-in-patients-with-multilevel-osteoporotic-vertebral-compression-fractures
#20
Eyal Behrbalk, Ofir Uri, Yoram Folman, Marcus Rickert, Radek Kaiser, Bronek Maximilian Boszczyk
Study Design Technical report. Objective Multilevel osteoporotic vertebral compression fractures may lead to considerable thoracic deformity and sagittal imbalance, which may necessitate surgical intervention. Correction of advanced thoracic kyphosis in patients with severe osteoporosis remains challenging, with a high rate of failure. This study describes a surgical technique of staged vertebral augmentation with osteotomies for the treatment of advanced thoracic kyphosis in patients with osteoporotic multilevel vertebral compression fractures...
November 2016: Global Spine Journal
label_collection
label_collection
4860
1
2
2016-10-28 12:58:55
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"